The Office of Drug Prevention, Treatment, and Enforcement in partnership with the Indiana Family and Social Services Administration - Division of Mental Health and Addiction and the Indiana Department of Health is developing a framework for how the State of Indiana plans to use the state portion of funds from the national opioid settlement with distributors McKesson, Cardinal Health and AmerisourceBergen and manufacturer Janssen Pharmaceuticals, Inc. and its parent company Johnson & Johnson. House Enrolled Act 1193, passed by the Indiana General Assembly and signed by Governor Eric J. Holcomb in March 2022, creates a 50/50 state and local split and defines the intensity metrics on how much money each locality will receive.
The State is using the Johns Hopkins Bloomberg School of Public Health's five guiding principles to ensure dollars are used most effectively:
- Spend the money to save lives
- Use evidence to guide spending
- Invest in youth prevention
- Focus on racial equity
- Develop a fair and transparent process for deciding where to spend the funds.
Exhibit E of the national settlement document outlines the approved abatement uses.
Check back for updates on Indiana's funding plan.
To submit questions or ideas for how opioid settlement funds should be spent, contact us at email@example.com.